查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933335

治疗性白蛋白市场

Therapeutic Albumin Market
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 186 Pages | 商品交期: 请询问到货日

价格

治疗性白蛋白市场成长因子

由于慢性疾病、创伤和烧伤病例的增加，全球治疗性白蛋白市场正经历稳定成长。治疗性白蛋白是一种主要从人类血浆中纯化的蛋白质。它在维持胶体渗透压、运输激素、酵素和药物以及治疗低血容量、烧伤、低白蛋白血症、急性肝衰竭和休息方面发挥着重要作用。重组白蛋白生产技术的进步以及在再生医学和细胞疗法领域应用的拓展，正在推动市场进一步成长。

预计2025年市场规模将达72.3亿美元，2026年成长至77亿美元，到2034年将达到133.3亿美元。预计2026年至2034年期间的复合年增长率（CAGR）为7.10%。亚太地区将在2025年占市场主导地位，市占率将达到55.49%，主要得益于该地区慢性病和烧伤的高发生率。

市场驱动因素与趋势

慢性病负担加重和烧伤病例增加

肝病、肾臟病和癌症盛行率的上升，以及烧伤病例的增加，正在推动市场成长。例如，在美国，2024年将有600万确诊肾病患者和450万确诊慢性肝病患者，2023年将有32,540例严重烧伤病例需要住院治疗。这表明，在液体復苏和重症监护环境中，对治疗性白蛋白的需求量很大。

白蛋白生产技术的进步

由于人源白蛋白存在供应短缺、病原体传播风险和批次间差异等局限性，各公司正在投资重组白蛋白和先进的白蛋白製剂。像Silpa Medicare的sRbumin（一种酵母来源的重组白蛋白）这样的创新技术正在弥补供应缺口，并提高安全性和稳定性。

再生医学的新应用

治疗性白蛋白的生物相容性和蛋白质稳定特性使其成为细胞治疗和组织工程的理想选择，为市场成长提供了新的机会。 Albumedix 和 Heartseed 等公司进行的合作研究计画正在探索重组白蛋白在心臟细胞治疗中的应用，从而拓展其临床应用范围。

市场挑战

监管障碍、高昂的生产成本和有限的人血浆供应仍然是主要挑战。 FDA、EMA 和 NMPA 的审批流程延缓了产品上市，发展中国家的供应和价格仍然是难题。供应链中断，例如美国红十字会预测的 2024 年美国血液短缺，进一步限制了市场成长。

市场区隔

依原料

  • 预计到 2026 年，人源白蛋白将占 65.17% 的市场占有率，主要受慢性疾病的普遍流行以及 Grifols、Octapharma 和 Kedrion 等公司强大的产品供应推动。
  • 为了克服供应限制，其他原料，包括重组白蛋白和植物源白蛋白，正受到越来越多的关注。

依适应症

  • 预计到 2026 年，烧伤护理将占 89.66% 的市场占有率，其主要目的是控制烧伤患者的体液流失。
  • 由过度出汗、腹泻或慢性心臟病和肾臟病等引起的低血容量的发生率正在稳步上升。
  • 低白蛋白血症和其他适应症呈现温和成长趋势。

依通路划分

  • 由于住院治疗和外科手术的需求，医院药局占市场主导地位（预计2026年市占率为54.56%）。
  • 零售药局提供广泛的药品供应。
  • 由于数位化程度的提高和送货上门的便利性，线上药局正在快速成长。

区域洞察

预计亚太地区将在2025年以40.1亿美元的市场规模引领市场，其次是日本（8.5亿美元）、中国（18.6亿美元）和印度（4.6亿美元），预计2026年这一数字将由慢性病和烧伤病例的普遍存在所驱动。

北美市场正经历稳定成长，预计到2026年，美国市场规模将达到15.2亿美元，这得益于其强大的血浆捐赠网路和先进的生产设施。

欧洲是第二大市场，预计到2026年，英国和德国的市场规模将分别达到1.8亿美元和2.8亿美元，主要得益于临床试验和研究活动的发展。

拉丁美洲和中东/非洲的市场规模较小，但由于慢性病盛行率的上升和血浆采集活动的扩大，预计这些地区的市场也将成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家和地区主要疾病流行情况（2025 年）
  • 概述：rHSA 产品参数
  • 主要公司新产品发布
  • 主要公司产品线分析
  • 主要产业趋势：併购、业务合作等
  • COVID-19 对全球的影响治疗性白蛋白市场

第五章 全球治疗性白蛋白市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依来源
    • 人源性
    • 其他
  • 市场分析、洞察与预测：依适应症
    • 低血容
    • 低白蛋白血症
    • 烧伤
    • 其他
  • 市场分析、洞察与预测：依分销管道
    • 医院药房
    • 零售药房
    • 线上药房
  • 市场分析、洞察与预测：依地区
    • 北美美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美治疗性白蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲治疗性白蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区治疗性白蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲治疗性白蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

    第十章：中东与非洲治疗性白蛋白市场分析：洞察与预测（2021-2034）

    • 依国家划分
      • 海湾地区海湾合作委员会 (GCC) 国家
      • 南非
      • 其他中东和非洲国家

    第十一章 竞争分析

    • 全球市占率分析（2025 年）
    • 公司简介
    • Takeda Pharmaceutical Company Limited.
    • CSL
    • Grifols, S.A.
    • Octapharma AG
    • Kedrion S.p.A.
    • Biotest AG
    • LFB(France)
    • China Biologic Products Holdings, Inc.
    • Baxter
Product Code: FBI112839

Growth Factors of therapeutic albumin Market

The global therapeutic albumin market is witnessing steady growth due to the increasing prevalence of chronic diseases, trauma, and burn injuries. Therapeutic albumin, a purified protein derived primarily from human blood plasma, plays a crucial role in maintaining oncotic pressure, transporting hormones, enzymes, and drugs, and treating hypovolemia, burns, hypoalbuminemia, acute liver failure, and shock. The market's expansion is further supported by advancements in recombinant albumin production and increasing applications in regenerative medicine and cell therapy.

In 2025, the market was valued at USD 7.23 billion, growing to USD 7.70 billion in 2026, and projected to reach USD 13.33 billion by 2034, registering a CAGR of 7.10% from 2026-2034. Asia Pacific dominated in 2025 with a 55.49% share, driven by a high incidence of chronic diseases and burn cases.

Market Drivers and Trends

Increasing Chronic Disease Burden and Burn Incidents

The rising prevalence of liver disorders, kidney diseases, and cancer, along with increasing burn injuries, is driving market growth. For instance, the U.S. had 6.0 million kidney disease cases and 4.5 million chronic liver disease cases in 2024, while 32,540 severe burn cases required hospitalization in 2023, highlighting the significant demand for therapeutic albumin in fluid resuscitation and critical care settings.

Advancements in Albumin Production

Due to limitations of human-derived albumin, such as supply shortages, pathogen transmission risk, and batch variability, companies are investing in recombinant albumin and advanced albumin formulations. Innovations like Shilpa Medicare's sRbumin, a yeast-derived recombinant albumin, address supply gaps and improve safety and consistency.

Emerging Applications in Regenerative Medicine

Therapeutic albumin's biocompatibility and protein stabilization properties make it ideal for cell therapy and tissue engineering, presenting new opportunities for market growth. Collaborations, such as Albumedix and Heartseed, are exploring recombinant albumin in cardiac cell therapy, indicating expanding clinical applications.

Market Challenges

Regulatory hurdles, high production costs, and limited availability of human plasma remain key challenges. Approval processes from the FDA, EMA, and NMPA slow product launches, while developing economies struggle with accessibility and affordability. Supply chain disruptions, such as the 2024 U.S. blood shortage reported by the American Red Cross, further constrain market growth.

Market Segmentation

By Source

  • Human-derived albumin dominates with a 65.17% share in 2026, driven by chronic disease prevalence and robust product offerings from companies like Grifols, S.A., Octapharma AG, and Kedrion S.p.A.
  • Other sources, including recombinant or plant-derived albumin, are gaining traction to overcome supply constraints.

By Indication

  • Burns account for 89.66% of the market in 2026, due to fluid loss management in burn patients.
  • Hypovolemia is growing steadily due to conditions like extreme perspiration, diarrhea, or chronic heart and kidney disease.
  • Hypoalbuminemia and other indications exhibit moderate growth.

By Distribution Channel

  • Hospital pharmacies dominate (54.56% in 2026) due to inpatient treatments and surgical procedures.
  • Retail pharmacies provide widespread accessibility.
  • Online pharmacies are growing rapidly, fueled by digital adoption and home delivery convenience.

Regional Insights

Asia Pacific dominated in 2025 with USD 4.01 billion, projected to lead with Japan at USD 0.85 billion, China at USD 1.86 billion, and India at USD 0.46 billion in 2026, driven by chronic disease prevalence and burn cases.

North America is growing steadily, with the U.S. market projected at USD 1.52 billion in 2026, benefiting from strong plasma donation networks and advanced manufacturing facilities.

Europe holds the second-largest market, with the UK at USD 0.18 billion and Germany at USD 0.28 billion in 2026, supported by clinical trials and research activities.

Latin America and the Middle East & Africa hold smaller shares but are expected to grow due to rising chronic disease prevalence and increasing plasma collection initiatives.

Competitive Landscape

Key players like Grifols, S.A., Octapharma AG, Kedrion S.p.A., Takeda Pharmaceutical, CSL, and China Biologic dominate the market through strategic acquisitions, collaborations, and new product launches. Notable developments include Grifols inaugurating a new purification plant in Dublin (2022) and Shilpa Medicare completing FDA inspection of its facility in India (2025), highlighting the focus on production capacity expansion and regulatory compliance.

Conclusion

The therapeutic albumin market is projected to grow from USD 7.23 billion in 2025 to USD 13.33 billion by 2034, driven by chronic disease prevalence, burn injuries, technological advancements in recombinant albumin, and expanding clinical applications in regenerative medicine. Asia Pacific remains the leading region, while North America and Europe continue steady growth. Challenges like supply constraints, regulatory barriers, and high production costs persist, but innovations in recombinant albumin and advanced formulations are expected to sustain market growth and improve global patient access to this vital therapeutic protein.

Segmentation By Source

  • Human
  • Others

By Indication

  • Hypovolemia
  • Hypoalbuminemia
  • Burn
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Source, Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Source, Indication, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Disorders: by Key Countries/Sub-regions, 2025
  • 4.2. Overview: rHSA Product Parameters
  • 4.3. New Product Launches, By Key Players
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Global Therapeutic Albumin Market

5. Global Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Source
    • 5.1.1. Human
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Hypovolemia
    • 5.2.2. Hypoalbuminemia
    • 5.2.3. Burn
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Source
    • 6.1.1. Human
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Hypovolemia
    • 6.2.2. Hypoalbuminemia
    • 6.2.3. Burn
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Source
    • 7.1.1. Human
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Hypovolemia
    • 7.2.2. Hypoalbuminemia
    • 7.2.3. Burn
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Source
    • 8.1.1. Human
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Hypovolemia
    • 8.2.2. Hypoalbuminemia
    • 8.2.3. Burn
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Source
    • 9.1.1. Human
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Hypovolemia
    • 9.2.2. Hypoalbuminemia
    • 9.2.3. Burn
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Therapeutic Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Source
    • 10.1.1. Human
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Hypovolemia
    • 10.2.2. Hypoalbuminemia
    • 10.2.3. Burn
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Takeda Pharmaceutical Company Limited.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. CSL
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Grifols, S.A.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Octapharma AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Kedrion S.p.A.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Biotest AG
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. LFB (France)
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. China Biologic Products Holdings, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Baxter
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 2: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 3: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 6: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 7: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 10: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 11: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 14: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 15: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 18: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 22: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 23: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Therapeutic Albumin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Therapeutic Albumin Market Value Share (%), by Source, 2025 & 2034
  • Figure 3: Global Therapeutic Albumin Market Value Share (%), by Indication, 2025 & 2034
  • Figure 4: Global Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Therapeutic Albumin Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Therapeutic Albumin Market Value (USD billion), by Source, 2025 & 2034
  • Figure 7: North America Therapeutic Albumin Market Value Share (%), by Source, 2025
  • Figure 8: North America Therapeutic Albumin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 9: North America Therapeutic Albumin Market Value Share (%), by Indication, 2025
  • Figure 10: North America Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Therapeutic Albumin Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Therapeutic Albumin Market Value Share (%), By Country, 2025
  • Figure 14: Europe Therapeutic Albumin Market Value (USD billion), by Source, 2025 & 2034
  • Figure 15: Europe Therapeutic Albumin Market Value Share (%), by Source, 2025
  • Figure 16: Europe Therapeutic Albumin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 17: Europe Therapeutic Albumin Market Value Share (%), by Indication, 2025
  • Figure 18: Europe Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Source, 2025 & 2034
  • Figure 23: Asia Pacific Therapeutic Albumin Market Value Share (%), by Source, 2025
  • Figure 24: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 25: Asia Pacific Therapeutic Albumin Market Value Share (%), by Indication, 2025
  • Figure 26: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Therapeutic Albumin Market Value (USD billion), by Source, 2025 & 2034
  • Figure 31: Latin America Therapeutic Albumin Market Value Share (%), by Source, 2025
  • Figure 32: Latin America Therapeutic Albumin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 33: Latin America Therapeutic Albumin Market Value Share (%), by Indication, 2025
  • Figure 34: Latin America Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Source, 2025 & 2034
  • Figure 39: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Source, 2025
  • Figure 40: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 41: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Indication, 2025
  • Figure 42: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Therapeutic Albumin Market Share (%), By Company, 2025